Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  ABLYNX    ABLX   BE0003877942

ABLYNX (ABLX)

Delayed Quote. Delayed  - 05/27 05:35:11 pm
14.19 EUR   +0.64%
05/26 ABLYNX : 26/05/2016 ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHA..
05/26 ABLYNX : TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY ..
05/13 ABLYNX : 13/05/2016 publication in accordance with article 14 of the..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 29TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/04/2011 | 06:10pm CEST

GHENT, Belgium, 4 January 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, 11 January 2011 at 11.00 a.m. PST / 08.00 p.m. CET.

 

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx's website at www.ablynx.com:
http://www.ablynx.com/. A replay of the webcast will also be available on the Company's website for 30 days following the presentation.

 

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

 

 

About Ablynx

Ablynx:
http://www.ablynx.com/ (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and Alzheimer's disease. Today, the Company has over 25 projects in the pipeline:
http://www.ablynx.com/en/research-development/pipeline/ and there are five Nanobodies in clinical development. In parallel with its internally developed products, Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 250 people. More information can be found on www.ablynx.com:
http://www.ablynx.com/.

 

 

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1477060/413118.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE


HUG#1477060


share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ABLYNX
05/26 ABLYNX : 26/05/2016 ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN ..
05/26 ABLYNX : TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACI..
05/13 ABLYNX : 13/05/2016 publication in accordance with article 14 of the belgian law..
05/13 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
05/12 ABLYNX : 12/05/2016 ablynx reports financial results for the first three months ..
05/12 ABLYNX : Reports financial results for the first three months of 2016 and provid..
05/09ABLYNX NV : quaterly earnings release
05/04 ABLYNX : Positive top line results from ALX-0171 infant RSV study
05/03 ABLYNX : REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (AL..
04/29 ABLYNX : 29/04/2016 ablynx announces milestone in drug discovery collaboration
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials